European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live
May 28

European equities traded in the US as American depositary receipts were trending slightly lower late Thursday morning, declining 0.1% to 1,873.2 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and medical device maker EDAP TMS (EDAP), which rose 3.3% and 3.2% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and software firm SAP (SAP), which were up 2.8% and 1.2% respectively.

The decliners from continental Europe were led by telecommunications company Nokia (NOK) and brewing company Anheuser-Busch InBev (BUD), which fell 2.5% and 1.4% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech firm BioNTech (BNTX), which were down 1.1% and 0.3% respectively.

The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which advanced 43.9% and 1.5% respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which increased 0.9% and 0.3% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and insurance company Prudential (PUK), which dropped 4.2% and 2.3% respectively. They were followed by lender HSBC (HSBC) and biopharmaceutical company Amarin (AMRN), which lost 2% and 0.6% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10